1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. ALK-Abelló A/S
  6. Summary
    ALK B   DK0061802139

ALK-ABELLÓ A/S

(ALK B)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Copenhagen
05/19/2022 05/20/2022 05/23/2022 05/24/2022 05/25/2022 Date
129.02(c) 133.32(c) 132.1(c) 132.38(c) 133.04(c) Last
254 882 365 000 157 978 153 202 236 066 Volume
+1.54% +3.33% -0.92% +0.21% +0.50% Change
More quotes
Estimated financial data (e)
Sales 2022 4 391 M 633 M 633 M
Net income 2022 352 M 50,8 M 50,8 M
Net Debt 2022 455 M 65,6 M 65,6 M
P/E ratio 2022 86,4x
Yield 2022 0,15%
Sales 2023 4 831 M 697 M 697 M
Net income 2023 636 M 91,7 M 91,7 M
Net Debt 2023 115 M 16,6 M 16,6 M
P/E ratio 2023 49,5x
Yield 2023 1,22%
Capitalization 29 297 M 4 224 M 4 224 M
EV / Sales 2022 6,78x
EV / Sales 2023 6,09x
Nbr of Employees 2 566
Free-Float 63,8%
More Financials
Company
ALK-Abello A/S is a Denmark-based company active within the pharmaceutical industry. It is engaged in the development and marketing of pharmaceutical products for the treatment, prevention and diagnosis of allergy. Its product portfolio comprises allergy vaccines, emergency treatments and allergy diagnostics products. The Company’s allergy vaccines product offering comprises tablet vaccines, sublingual vaccines... 
Sector
Pharmaceuticals
Calendar
08/11Earnings Release
More about the company
Ratings of ALK-Abelló A/S
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about ALK-ABELLÓ A/S
05/19Report on transactions with ALK-Abelló A/S B-shares and associated securities by manage..
GL
05/19Alk-Abelló A/S Announces Executive Changes
CI
05/17Report on transactions with ALK-Abelló A/S B-shares and associated securities by manage..
GL
05/17Report on transactions with ALK-Abelló A/S B-shares and associated securities by manage..
GL
05/12TRANSCRIPT : ALK-Abelló A/S, Q1 2022 Earnings Call, May 12, 2022
CI
05/12Three-month interim report (Q1) 2022
GL
05/12Three-month interim report (Q1) 2022
AQ
05/12ALK-Abelló A/S Provides Earnings Guidance for the Year 2022
CI
05/12ALK-Abelló A/S Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/03Release date of three-month interim report (Q1) 2022 for ALK and audio cast
GL
03/28ALK-ABELLÓ A/S : SPLIT: 20 of 1
FA
03/24Grant of share options and performance shares to members of the Board of Management and..
AQ
03/16DECISION TO COMPLETE SHARE SPLIT AT : 20
GL
03/16Annual General Meeting in ALK-Abelló A/S held on 16 March 2022
GL
03/16Annual General Meeting in ALK-Abelló A/S held on 16 March 2022
GL
More news
News in other languages on ALK-ABELLÓ A/S
05/19Alk-Abelló A/S annonce des changements de direction
05/12ALK-Abelló A/S fournit des prévisions de bénéfices pour l'année 2022
05/12ALK-Abelló A/S annonce ses résultats pour le premier trimestre clos le 31 mars 2022
03/03ALK prévoit de soumettre une demande d'enregistrement en Chine pour son comprimé d'immu..
02/08ALK-Abelló ; A/S fournit des prévisions de bénéfices pour l'exercice 2022
More news
Chart ALK-ABELLÓ A/S
Duration : Period :
ALK-Abelló A/S Technical Analysis Chart | ALK B | DK0061802139 | MarketScreener
Technical analysis trends ALK-ABELLÓ A/S
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 133,04 DKK
Average target price 169,88 DKK
Spread / Average Target 27,7%
EPS Revisions
Managers and Directors
Carsten Hellmann President & Chief Executive Officer
Søren Jelert Chief Financial Officer & Executive Vice President
Anders Hedegaard Chairman
Henrik Hugo Jacobi Executive Vice President-Research & Development
Gonzalo de Miquel Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ALK-ABELLÓ A/S-22.43%4 205
JOHNSON & JOHNSON5.00%472 652
PFIZER, INC.-9.04%301 361
ROCHE HOLDING AG-12.16%281 908
ELI LILLY AND COMPANY11.15%276 358
ABBVIE INC.12.23%268 530